Stem cell holdings criticized
<p class="source">Sacramento Bee</p>
<p>Ten of the 29 directors of California's new stem cell program serve on biotech or pharmaceutical firms' boards of directors or have extensive holdings in those industries, leading critics to challenge their ability to fairly represent taxpayers in dolin</p>
